Taia

List of Publications by Year
in descending order

41 papers	7,084 citations	279798 23 h-index	395702 33 g-index
57 all docs	57 docs citations	57 times ranked	16446 citing authors

#	Article	IF	Citations
1	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 2022, 19, 475-495.	13.7	180
2	Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Science Translational Medicine, 2022, 14, eabm7853.	12.4	71
3	Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Science Translational Medicine, 2022, 14, eabn7842.	12.4	92
4	Differential Peripheral Blood Glycoprotein Profiles in Symptomatic and Asymptomatic COVID-19. Viruses, 2022, 14, 553.	3.3	7
5	TNF-Î±+ CD4+ TÂcells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell Reports Medicine, 2022, 3, 100640.	6.5	15
6	Heterogeneity in IgGâ€CD16 signaling in infectious disease outcomes*. Immunological Reviews, 2022, 309, 64-74.	6.0	9
7	Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to postâ€“COVID-19 syndrome. JCI Insight, 2022, 7, .	5.0	18
8	Harnessing IgG Fc glycosylation for clinical benefit. Current Opinion in Immunology, 2022, 77, 102231.	5.5	3
9	Proinflammatory IgG Fc structures in patients with severe COVID-19. Nature Immunology, 2021, 22, 67-73.	14.5	239
10	Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nature Communications, 2021, 12, 1967.	12.8	107
11	Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. Nature Biotechnology, 2021, 39, 928-935.	17.5	106
12	Immunity after SARS-CoV-2 infections. Nature Immunology, 2021, 22, 539-540.	14.5	20
13	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. Advanced Drug Delivery Reviews, 2021, 172, 314-338.	13.7	75
14	An aberrant inflammatory response in severe COVID-19. Cell Host and Microbe, 2021, 29, 1043-1047.	11.0	24
15	Illuminating the Fc dependence of SARS-CoV-2 neutralization. Immunity, 2021, 54, 1912-1914.	14.3	1
16	New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nature Communications, 2021, 12, 5417.	12.8	286
17	Immunoglobulin E sialylation regulates allergic responses. Immunology and Cell Biology, 2020, 98, 617-619.	2.3	2
18	Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2. Cell Host and Microbe, 2020, 28, 516-525.e5.	11.0	219

#	ARTICLE	IF	CITATIONS
19	Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. MSphere, 2020, 5, .	2.9	62
20	Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Science Immunology, 2020, 5, .	11.9	404
21	Maternal Anti-Dengue IgG Fucosylation Predicts Susceptibility to Dengue Disease in Infants. Cell Reports, 2020, 31, 107642.	6.4	44
22	Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell, 2020, 181, 1036-1045.e9.	28.9	3,572
23	FcRn, but not FcÎ³Rs, drives maternal-fetal transplacental transport of human IgG antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12943-12951.	7.1	55
24	IgG Fc Glycosylation in Human Immunity. Current Topics in Microbiology and Immunology, 2019, 423, 63-75.	1.1	38
25	Functional diversification of IgGs through Fc glycosylation. Journal of Clinical Investigation, 2019, 129, 3492-3498.	8.2	115
26	Immunity by Design. Cell Host and Microbe, 2018, 23, 430-431.	11.0	3
27	Immunological responses to influenza vaccination: lessons for improving vaccine efficacy. Current Opinion in Immunology, 2018, 53, 124-129.	5.5	24
28	IgG antibodies to dengue enhanced for FcÎ³RIIIA binding determine disease severity. Science, 2017, 355, 395-398.	12.6	286
29	Signaling by Antibodies: Recent Progress. Annual Review of Immunology, 2017, 35, 285-311.	21.8	167
30	Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10172-10177.	7.1	42
31	The Role and Function of FcÎ³ Receptors on Myeloid Cells. , 2017, , 405-427.		8
32	The Role and Function of FcÎ³ Receptors on Myeloid Cells. Microbiology Spectrum, 2016, 4, .	3.0	96
33	Influenza antibody archaeology. Science Translational Medicine, 2016, 8, .	12.4	0
34	A puzzling path from infection to Guillain-BarrÃ© syndrome. Science Translational Medicine, 2016, 8, .	12.4	0
35	Immune Complexes: Not Just an Innocent Bystander in Chronic Viral Infection. Immunity, 2015, 42, 213-215.	14.3	20
36	Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell, 2015, 162, 160-169.	28.9	171

#	Article	IF	Citations
37	Original antigenic sin strikes again?. Science Translational Medicine, 2015, 7, .	12.4	0
38	Two-pronged approach to prevent pneumonia. Science Translational Medicine, 2015, 7, .	12.4	0
39	Passenger mutations: Backseat drivers in failed translation. Science Translational Medicine, 2015, 7, .	12.4	0
40	Polypharmacy repercussions. Science Translational Medicine, 2015, 7, .	12.4	0
41	Type I and type II Fc receptors regulate innate and adaptive immunity. Nature Immunology, 2014, 15, 707-716.	14.5	425